Sunday, November 8, 2009

Positive Phase 2 results of Telaprevir...

I did mention about telaprevir (structure) in my earlier blog, and following other developments for hepatitis C (blogs). Now Vertex Pharmaceuticals has announced the results of Phase 2.

The results are really encouraging and as per the claim by the company "more than 80 percent of hepatitis C patients in each arm of the Phase 2 Study C208 achieved a sustained viral response (SVR) with a telaprevir-based regimen according to results of an intent-to-treat (ITT) analysis".

Across the four arms, SVR rates were 82 and 83 percent in patients treated with the every 12 hour telaprevir-based regimen (PEGINTRON and PEGASYS, respectively) and 81 and 85 percent in patients treated with the every 8 hour regimen (PEGINTRON and PEGASYS, respectively). For the majority of patients, these SVR rates were obtained with a 24-week telaprevir-based regimen.

Ref :

No comments: